tiprankstipranks
Roche Holding AG (CH:ROP)
:ROP
Switzerland Market
ROP
Roche Holding AG
RESEARCH TOOLSreports
Want to see CH:ROP full AI Analyst Report?

Roche Holding AG (ROP) Stock Forecast & Price Target

79 Followers
See the Price Targets and Ratings of:

ROP Analyst Ratings

Moderate Buy
11Ratings
Moderate Buy
4 Buy
6 Hold
1 Sell
Based on 11 analysts giving stock ratings to
Roche
Holding AG
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ROP Stock 12 Month Forecast

Average Price Target

CHF347.40
▲(8.56% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Roche Holding AG in the last 3 months. The average price target is CHF347.40 with a high forecast of CHF415.00 and a low forecast of CHF230.00. The average price target represents a 8.56% change from the last price of CHF320.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"229":"CHF229","416":"CHF416","275.75":"CHF275.8","322.5":"CHF322.5","369.25":"CHF369.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":415,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF415.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":347.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF347.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":230,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF230.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[229,275.75,322.5,369.25,416],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,317.4,324.9076923076923,332.4153846153846,339.9230769230769,347.4307692307692,354.9384615384615,362.44615384615383,369.95384615384614,377.46153846153845,384.96923076923076,392.4769230769231,399.9846153846154,407.4923076923077,{"y":415,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,317.4,319.7076923076923,322.0153846153846,324.3230769230769,326.6307692307692,328.9384615384615,331.24615384615385,333.5538461538461,335.86153846153843,338.16923076923075,340.4769230769231,342.78461538461534,345.09230769230766,{"y":347.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,317.4,310.67692307692306,303.95384615384614,297.2307692307692,290.5076923076923,283.7846153846154,277.0615384615385,270.3384615384615,263.6153846153846,256.89230769230767,250.16923076923075,243.44615384615383,236.72307692307692,{"y":230,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":256.839,"date":1748736000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":252.958,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":249.464,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 14</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":252.472,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":273.916,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":251.211,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 20</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":299.823,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":318.453,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":343.972,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":352.123,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.3,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":318.4,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":317.4,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetCHF415.00Average Price TargetCHF347.40Lowest Price TargetCHF230.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on CH:ROP
James Quigley
Goldman Sachs
Goldman Sachs
CHF346→CHF348
Hold
8.75%
Upside
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL) and Roche Holding AG (Other OTC: RHHVF)
Jefferies Analyst forecast on CH:ROP
Michael Leuchten
Jefferies
Jefferies
CHF230
Sell
-28.13%
Downside
Reiterated
06/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (NASDAQ: APGE), Inventiva (NASDAQ: IVA) and Roche Holding AG (Other OTC: RHHVF)
Deutsche Bank Analyst forecast on CH:ROP
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
CHF340
Hold
6.25%
Upside
Reiterated
05/27/26
Deutsche Bank Sticks to Their Hold Rating for Roche Holding AG (RHHVF)
Barclays Analyst forecast on CH:ROP
James Gordon CFA
Barclays
Barclays
CHF410
Buy
28.13%
Upside
Reiterated
05/26/26
Analysts Are Bullish on These Healthcare Stocks: Roche Holding AG (RHHVF), Cingulate Inc (CING)
UBS Analyst forecast on CH:ROP
Matthew Weston
UBS
UBS
CHF384→CHF376
Buy
17.50%
Upside
Reiterated
05/13/26
UBS Sticks to Its Buy Rating for Roche Holding AG (RHHVF)
Berenberg Bank Analyst forecast on CH:ROP
Luisa Hector
Berenberg Bank
Berenberg Bank
CHF340
Hold
6.25%
Upside
Reiterated
05/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (Other OTC: CMXHF), Roche Holding AG (Other OTC: RHHVF) and Pfizer (NYSE: PFE)
Erste Group Analyst forecast on CH:ROP
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
05/04/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
J.P. Morgan Analyst forecast on CH:ROP
Richard Vosser
J.P. Morgan
J.P. Morgan
CHF325
Hold
1.56%
Upside
Reiterated
05/01/26
J.P. Morgan Sticks to Their Hold Rating for Roche Holding AG (RHHVF)
Bernstein Analyst forecast on CH:ROP
Justin Smith
Bernstein
Bernstein
CHF395
Buy
23.44%
Upside
Assigned
04/27/26
Analyst Reiterates Buy on Roche, Maintains CHF 395 Price Target on Underappreciated Long-Term Pipeline Upside
Morgan Stanley Analyst forecast on CH:ROP
Sarita Kapila
Morgan Stanley
Morgan Stanley
CHF295
Hold
-7.81%
Downside
Upgraded
04/24/26
Roche upgraded to Equal Weight from Underweight at Morgan StanleyRoche upgraded to Equal Weight from Underweight at Morgan Stanley
Kepler Capital Analyst forecast on CH:ROP
David Evans
Kepler Capital
Kepler Capital
CHF415
Buy
29.69%
Upside
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Sanofi (Other OTC: SNYNF)
HSBC Analyst forecast on CH:ROP
Unknown Analyst
HSBC
Not Ranked
HSBC
CHF385→CHF365
Buy
14.06%
Upside
Reiterated
03/10/26
Roche Holding AG target price reduced from CHF385 to CHF365, but we maintain our Buy rating due to pipeline catalysts.
Citi Analyst forecast on CH:ROP
Graham Parry
Citi
Citi
―
Buy
―
Reiterated
03/10/26
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), BioNTech SE (NASDAQ: BNTX) and Skye Bioscience (NASDAQ: SKYE)
DZ BANK AG Analyst forecast on CH:ROP
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
02/02/26
Analysts' Top Healthcare Picks: Nektar Therapeutics (NKTR), Roche Holding AG (RHHVF)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Goldman Sachs Analyst forecast on CH:ROP
James Quigley
Goldman Sachs
Goldman Sachs
CHF346→CHF348
Hold
8.75%
Upside
Reiterated
06/30/26
Analysts Offer Insights on Healthcare Companies: Replimune Group (NASDAQ: REPL) and Roche Holding AG (Other OTC: RHHVF)
Jefferies Analyst forecast on CH:ROP
Michael Leuchten
Jefferies
Jefferies
CHF230
Sell
-28.13%
Downside
Reiterated
06/08/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Apogee Therapeutics (NASDAQ: APGE), Inventiva (NASDAQ: IVA) and Roche Holding AG (Other OTC: RHHVF)
Deutsche Bank Analyst forecast on CH:ROP
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
CHF340
Hold
6.25%
Upside
Reiterated
05/27/26
Deutsche Bank Sticks to Their Hold Rating for Roche Holding AG (RHHVF)
Barclays Analyst forecast on CH:ROP
James Gordon CFA
Barclays
Barclays
CHF410
Buy
28.13%
Upside
Reiterated
05/26/26
Analysts Are Bullish on These Healthcare Stocks: Roche Holding AG (RHHVF), Cingulate Inc (CING)
UBS Analyst forecast on CH:ROP
Matthew Weston
UBS
UBS
CHF384→CHF376
Buy
17.50%
Upside
Reiterated
05/13/26
UBS Sticks to Its Buy Rating for Roche Holding AG (RHHVF)
Berenberg Bank Analyst forecast on CH:ROP
Luisa Hector
Berenberg Bank
Berenberg Bank
CHF340
Hold
6.25%
Upside
Reiterated
05/08/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: CSL (Other OTC: CMXHF), Roche Holding AG (Other OTC: RHHVF) and Pfizer (NYSE: PFE)
Erste Group Analyst forecast on CH:ROP
Hans Engel
Erste Group
Erste Group
―
Hold
―
Reiterated
05/04/26
Wall Street Analysts Are Neutral on Top Healthcare Picks
J.P. Morgan Analyst forecast on CH:ROP
Richard Vosser
J.P. Morgan
J.P. Morgan
CHF325
Hold
1.56%
Upside
Reiterated
05/01/26
J.P. Morgan Sticks to Their Hold Rating for Roche Holding AG (RHHVF)
Bernstein Analyst forecast on CH:ROP
Justin Smith
Bernstein
Bernstein
CHF395
Buy
23.44%
Upside
Assigned
04/27/26
Analyst Reiterates Buy on Roche, Maintains CHF 395 Price Target on Underappreciated Long-Term Pipeline Upside
Morgan Stanley Analyst forecast on CH:ROP
Sarita Kapila
Morgan Stanley
Morgan Stanley
CHF295
Hold
-7.81%
Downside
Upgraded
04/24/26
Roche upgraded to Equal Weight from Underweight at Morgan StanleyRoche upgraded to Equal Weight from Underweight at Morgan Stanley
Kepler Capital Analyst forecast on CH:ROP
David Evans
Kepler Capital
Kepler Capital
CHF415
Buy
29.69%
Upside
Reiterated
04/23/26
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF) and Sanofi (Other OTC: SNYNF)
HSBC Analyst forecast on CH:ROP
Unknown Analyst
HSBC
Not Ranked
HSBC
CHF385→CHF365
Buy
14.06%
Upside
Reiterated
03/10/26
Roche Holding AG target price reduced from CHF385 to CHF365, but we maintain our Buy rating due to pipeline catalysts.
Citi Analyst forecast on CH:ROP
Graham Parry
Citi
Citi
―
Buy
―
Reiterated
03/10/26
Analysts Offer Insights on Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), BioNTech SE (NASDAQ: BNTX) and Skye Bioscience (NASDAQ: SKYE)
DZ BANK AG Analyst forecast on CH:ROP
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Buy
―
Reiterated
02/02/26
Analysts' Top Healthcare Picks: Nektar Therapeutics (NKTR), Roche Holding AG (RHHVF)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Roche Holding AG

3 Months
David EvansKepler Capital
Success Rate
15/19 ratings generated profit
79%
Average Return
+8.09%
Copying David Evans's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +8.09% per trade.
1 Year
Matthew WestonUBS
Success Rate
14/14 ratings generated profit
100%
Average Return
+24.12%
Copying Matthew Weston's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +24.12% per trade.
2 Years
Justin SmithBernstein
Success Rate
16/16 ratings generated profit
100%
Average Return
+32.52%
Copying Justin Smith's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +32.52% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ROP Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
16
25
21
19
8
Hold
21
22
13
13
7
Sell
7
6
6
4
4
Strong Sell
0
0
0
0
0
total
44
53
40
36
19
In the current month, ROP has received 8 Buy Ratings, 7 Hold Ratings, and 4 Sell Ratings. ROP average Analyst price target in the past 3 months is 347.40.
Each month's total comprises the sum of three months' worth of ratings.

ROP Financial Forecast

ROP Earnings Forecast

Next quarter’s earnings estimate for ROP is CHF10.03 with a range of CHF9.36 to CHF10.61. The previous quarter’s EPS was CHF8.38. ROP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ROP has Performed in-line its overall industry.
Next quarter’s earnings estimate for ROP is CHF10.03 with a range of CHF9.36 to CHF10.61. The previous quarter’s EPS was CHF8.38. ROP beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year ROP has Performed in-line its overall industry.

ROP Sales Forecast

Next quarter’s sales forecast for ROP is CHF15.61B with a range of CHF15.49B to CHF15.73B. The previous quarter’s sales results were CHF30.57B. ROP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ROP has Performed in-line its overall industry.
Next quarter’s sales forecast for ROP is CHF15.61B with a range of CHF15.49B to CHF15.73B. The previous quarter’s sales results were CHF30.57B. ROP beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year ROP has Performed in-line its overall industry.

ROP Stock Forecast FAQ

What is CH:ROP’s average 12-month price target, according to analysts?
Based on analyst ratings, Roche Holding AG’s 12-month average price target is 347.40.
    What is CH:ROP’s upside potential, based on the analysts’ average price target?
    Roche Holding AG has 8.56% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Roche Holding AG a Buy, Sell or Hold?
          Roche Holding AG has a consensus rating of Moderate Buy, which is based on 4 buy ratings, 6 hold ratings and 1 sell ratings.
            What is Roche Holding AG’s share price target?
            The average share price target for Roche Holding AG is 347.40. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is CHF415.00 ,and the lowest forecast is CHF230.00. The average share price target represents 8.56% Increase from the current price of CHF320.
              What do analysts say about Roche Holding AG?
              Roche Holding AG’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Roche Holding AG?
                To buy shares of CH:ROP, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.